Funded Research

Research Pilot Award Recipients (2023 - Round 2)

• Anil Bidkar, PhD and Scott Bidlingmaier, PhD
  Actinium-225/MMAE Dual-Loaded Antibody Drug Conjugate for Prostate Cancer Targeted Therapy
• Peter Bruno, PhD
  Towards Identifying the Immunopeptidome of Prostate Cancer and its Role in Disease Progression
• Lisa Chesner, PhD
  Investigation of Wee1 inhibition for ATM-deficient prostate cancer
• Cornelia Ding, MD, PhD  and David Quigley, PhD
  The Molecular Pathologic Characterization of Double-Negative Metastatic Prostate Cancer
• Aidan Pace
  Effects of an Exercise Program on Markers of Inflammation and Insulinemia in Men on Active Surveillance for Prostate Cancer
• Kimberly Rickman, MD, PhD
  Defining prostate cancer tumor-immune system interactions in BRCA2 deficiency to identify therapeutic vulnerabilities
• Jiuling Yang, MD, PhD
  Unraveling the role of PVRL2 in tumor development and determining its therapeutic potential 
• Xiaolin Zhu, MD, PhD
  Investigating SSTR1 in Resistance to Androgen Receptor Signaling Inhibitors in Prostate Cancer

Research Pilot Award Recipients (2023 - Round 1)

• Jonathan Chou, MD, PhD
  Inhibition as a Therapeutic Strategy for CDK12-Mutated Prostate Cancer
• Erin Van Blarigan, ScD
  Eating Better Together: Developing a Dyadic Dietary Intervention for Prostate Cancer Patients and their Partners
• Meng Zhang, MSc, PhD
  Investigation of Microproteins as Novel Druggable Targets in Prostate Cancer

About the Prostate Cancer Program Pilot Research Awards

The UCSF Prostate Cancer Program funds pilot projects in all areas of prostate cancer research at UCSF, including computational, laboratory, translational, clinical, and population sciences. Learn more about this program.

RAP Fall 2023 Cycle Awardees

• Jennifer Rosenbluth, MD, PhD
  Breast Organoids as Models for Cancer Interception
• Aaron Diaz, PhD
  Targeting ZSCAN4 mediated telomere repair in pediatric brain tumors
• Arpita Desai, MD
  Investigation of Hyperpolarized 13 C MRI to assess treatment response in metastatic kidney cancer
• Manish Aghi, MD, PhD
  Skull Bone Marrow Contributes Antigen Presenting Hybrid Neutrophils to the Glioblastoma Microenvironment
• Katherine Wai, MD
  Defining the Immune Response to Checkpoint Inhibition in Head and Neck Cancer
• Gregory Allen, MD, PhD
  Establishing new more rigorous pancreatic tumor models for pre-clinical evaluation of next-gen CAR T cell designs

For more information on the cancer research projects above, read our news story.

About the RAP Awards

The Resource Allocation Program (RAP) is a campus-wide program whose aim is to coordinate intramural research funding opportunities for the UCSF community. Through RAP, the Cancer Center and other UCSF agencies provide seed funding to encourage clinical investigators, especially those at the beginning of their career, to initiate promising projects that may enable them to compete successfully for national research grants. Targeted areas are innovative pilot and phase I/II studies and other projects in clinical, health policy, health services, and psychosocial and behavioral research.

Beginning in 2022, 13 travel and publication stipends have been awarded to HDFCCC Clinical Research staff who are working with HDFCCC faculty on a research project. The awards have covered travel to research conferences and publication in journals. View the full RFA.

Congratulations to following recipients (and their faculty mentors):

• Miranda Gilbert and Lucy Fu (Dr. Arun Rangaswami)
• Tanya Jindal (Dr. Vadim Koshkin)
• Nathalie Kacik (Dr. Hope Rugo)
• Bryan Khuong Le (Dr. Emily Bergsland)
• Tina Kim (Dr. Hope Rugo)
• Farhada Moon (Dr. Emily Bergsland)
• Victoria Onyike (Dr. Lee-May Chen)
• Divita Pandita (Dr. Babis Andreadis)
• Brianna Roque and Kenzie Johnson (Dr. Jo Chien)
• Nonna Shakhnazaryan (Dr. Eric Small & Dr. Daniel Kwon)
• Evelin Trejo (Dr. Ana Velázquez Mañana)
• Karina Wong (Dr. Kieuhoa Vo) 

The Cancer League 2023 Awardees

• Elliot Stieglitz, MD
  Using the immune system to treat infant leukemia
• Mike Rabow, MD
  Sustaining Cancer Care Partners Throughout the Cancer Journey
• Hugo Gonzalez Velozo, PhD
  Interrogating cellular crosstalk in human brain metastasis using 3D tumor-host assembloids
• Robert Goldsby, MD
  Utilizing A Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
• Vadim Koshkin, MD
  Clinicogenomic profiles and treatment outcomes of HER2-expressing and HER2-altered urothelial cancer

The Cancer League 2022 Awardees

• Robert Flavell, MD, PhD
  Prostate Specific Membrane Antigen Targeted [177Lu] Labeled Nanomedicines to Treat Prostate Cancer
• Alex Marson, MD, PhD
  Unlocking the Cancer-killing Capacity of γδ T Cells

About The Cancer League

The Cancer League’s primary interest is in funding projects in early stage research and/or supporting and assisting patients through their cancer journey. Their mission is to support the fight against cancer in such areas as early detection, education, patient care services and research for various types of cancer for men, women and children.

In 2022, the Helen Diller Family Comprehensive Cancer Center funded 25 promising pilot projects totaling $1 million to support cancer research in strategic and developing areas. The projects span basic, translational, and population science from early career and established investigators.

View the full list of awardees.

• Charles Craik, PhD and Michael Evans, PhD
  Beyond ligand/receptor complexes: maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe.
• Adam Renslo, PhD and Michael Evans, PhD
  Evaluating the in vivo efficacy and molecular pharmacology of artefenomel in castration-resistant prostate cancer models.
• Michael McManus, PhD
  Unlocking the key drivers and dependencies of Prostate Cancer using CRISPR GEMMS

About the BIPCR Molecular Oncology Program Awards

The Benioff Initiative for Prostate Cancer Research has provided project funding to support proposals from the HDFCCC Molecular Oncology Program. The funding is intended to address the serious unmet need for new therapeutic treatments for prostate cancer patients, particularly those with aggressive metastatic disease.